Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A07XA06
|
| gptkbp:brand |
crofelemer
|
| gptkbp:derivedFrom |
Croton lechleri (dragon's blood) sap
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fulyzaq
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Napo_Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
chloride channel inhibitor
|
| gptkbp:sideEffect |
bronchitis
cough flatulence upper respiratory tract infection increased bilirubin |
| gptkbp:usedFor |
treatment of non-infectious diarrhea in HIV/AIDS patients
|
| gptkbp:bfsParent |
gptkb:Crofelemer
|
| gptkbp:bfsLayer |
8
|